154 related articles for article (PubMed ID: 18625668)
1. Assessment of regional progression of pulmonary emphysema with CT densitometry.
Bakker ME; Putter H; Stolk J; Shaker SB; Piitulainen E; Russi EW; Stoel BC
Chest; 2008 Nov; 134(5):931-937. PubMed ID: 18625668
[TBL] [Abstract][Full Text] [Related]
2. CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency.
Holme J; Stockley RA
Chest; 2009 Nov; 136(5):1284-1290. PubMed ID: 19892672
[TBL] [Abstract][Full Text] [Related]
3. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.
Parr DG; Dirksen A; Piitulainen E; Deng C; Wencker M; Stockley RA
Respir Res; 2009 Aug; 10(1):75. PubMed ID: 19678952
[TBL] [Abstract][Full Text] [Related]
4. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age.
Piitulainen E; Montero LC; Nystedt-Düzakin M; Stoel BC; Sveger T; Wollmer P; Tanash HA; Diaz S
COPD; 2015 Apr; 12(2):162-7. PubMed ID: 25280185
[TBL] [Abstract][Full Text] [Related]
5. Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency.
Parr DG; Stoel BC; Stolk J; Stockley RA
Thorax; 2006 Jun; 61(6):485-90. PubMed ID: 16537666
[TBL] [Abstract][Full Text] [Related]
6. Regional lung densities in alpha-1 antitrypsin deficiency compared to predicted values.
Stoel BC; Stolk J; Bakker ME; Parr DG
Respir Res; 2019 Feb; 20(1):45. PubMed ID: 30819163
[TBL] [Abstract][Full Text] [Related]
7. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
8. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.
Mostafavi B; Diaz S; Piitulainen E; Stoel BC; Wollmer P; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2018; 13():3689-3698. PubMed ID: 30510411
[TBL] [Abstract][Full Text] [Related]
9. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.
Dirksen A; Piitulainen E; Parr DG; Deng C; Wencker M; Shaker SB; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1345-53. PubMed ID: 19196813
[TBL] [Abstract][Full Text] [Related]
10. Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency.
Sandhaus RA
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S370-3. PubMed ID: 27564674
[TBL] [Abstract][Full Text] [Related]
11. Influence of calibration on densitometric studies of emphysema progression using computed tomography.
Parr DG; Stoel BC; Stolk J; Nightingale PG; Stockley RA
Am J Respir Crit Care Med; 2004 Oct; 170(8):883-90. PubMed ID: 15271692
[TBL] [Abstract][Full Text] [Related]
12. CT lung densitometry in young adults with alpha-1-antitrypsin deficiency.
Bernspång E; Diaz S; Stoel B; Wollmer P; Sveger T; Piitulainen E
Respir Med; 2011 Jan; 105(1):74-9. PubMed ID: 20674322
[TBL] [Abstract][Full Text] [Related]
13. CT densitometry in emphysema: a systematic review of its clinical utility.
Crossley D; Renton M; Khan M; Low EV; Turner AM
Int J Chron Obstruct Pulmon Dis; 2018; 13():547-563. PubMed ID: 29445272
[TBL] [Abstract][Full Text] [Related]
14. European screening for alpha
Greulich T; Averyanov A; Borsa L; Rozborilová E; Vaicius D; Major T; Chopyak V; Tudorache V; Konstantinova T; Camprubí S
Clin Respir J; 2017 Jan; 11(1):90-97. PubMed ID: 25919395
[TBL] [Abstract][Full Text] [Related]
15. Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT.
Dirksen A; Friis M; Olesen KP; Skovgaard LT; Sørensen K
Acta Radiol; 1997 Sep; 38(5):826-32. PubMed ID: 9332238
[TBL] [Abstract][Full Text] [Related]
16. Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; methodological advances.
Parr DG; Sevenoaks M; Deng C; Stoel BC; Stockley RA
Respir Res; 2008 Feb; 9(1):21. PubMed ID: 18271964
[TBL] [Abstract][Full Text] [Related]
17. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
18. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
19. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment.
Parr DG; Stoel BC; Stolk J; Stockley RA
Am J Respir Crit Care Med; 2004 Dec; 170(11):1172-8. PubMed ID: 15306534
[TBL] [Abstract][Full Text] [Related]
20. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.
O'Brien ME; Pennycooke K; Carroll TP; Shum J; Fee LT; O'Connor C; Logan PM; Reeves EP; McElvaney NG
COPD; 2015 May; 12 Suppl 1():2-9. PubMed ID: 25938284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
